This drug is the first FDA-approved IDH1 inhibitor and will be used to treat adult patients with relapsed or refractory acute myeloid leukemia.

By applying the plasmonic patch as a final step in assay development, diagnostic test developers will be able to increase fluorescence intensity onehundred-fold.

The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.

The firm’s two-step multiplexed-tandem PCR tool identifies low concentrations of multiple STI pathogens in samples with high concentrations of other pathogens in three hours.

The recent OIG report on the implementation of PAMA doesn’t address that CMS has ignored congressional intent in implementing the law, ACLA said.

Formerly known as SlipChip Corp, the firm has recently won nearly $10 million in funding to hone its approaches to sepsis and CT/NG testing.